Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Hansa Biopharma AB
HNSAHansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden. Address: ScheelevAegen 22, Lund, Sweden, 223 63
Analytics
Precio Objetivo de WallStreet
1 225.61 SEKRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave HNSA
Análisis de dividendos HNSA
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout HNSA
Valoración de la acción HNSA
Finanzas HNSA
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |